NovelStem International Corp., a biotechnology company focused on the stem cell-based technology platform developed by 30%-owned Israel-based, NewStem, Ltd., announced that NewStem was selected by Illumina for its global Illumina Accelerator. Under the agreement, NewStem is entitled to a match funding for new capital of up to $5.5 million within 18 months. 

Illumina, Inc. has selected NewStem as one of seven new genomics companies to join the third global funding cycle of Illumina Accelerator. NewStem Ltd. , a cancer therapeutics and diagnostics company from Israel, is developing genetic-based products utilizing a proprietary haploid human embryonic stem cells library of mutations.